Résultats de la recherche

Tous les résultats
Par Categories
Other news (69)
Autres actus (23)
Jobs (14)
Seminars (13)
Distinctions / Prix (12)
Offres d'emploi (6)
News (5)
Actualités (4)
Edito (3)
Séminaires / Colloques (2)
Awards / Prizes (1)
Groupe modélisation (1)
Nomination (1)
Uncategorized (1)
Par Tags
chromatin (9)
breast cancer (8)
Page Labex (6)
cell polarity (6)
cytoskeleton (6)
epigenetics (6)
genome stability (6)
cell division (5)
cell migration (4)
chromatine (4)
division cellulaire (4)
evolution (4)
immunotherapy (4)
metastasis (4)
microfluidics (4)
molecular motors (4)
mouse models (4)
DNA repair (3)
Homologous Recombination (3)
Recombinaison Homologue (3)
Affichage des résultats 1 à 20 sur 6770
transposases, prDSBs have been integrated in the life cycle of ciliates. Created by Spo11 during meiotic...

Par Domaine 2 - UMR3244, le 12/13/2019

reporting immune-related side effects with FDG PET based on published data and experts' experience...

Par Domaine 3 - U900, le 12/10/2019

; Chelouah et al. PLoS One 6:e23597, 2011)) with no dose reductions. At DL 10 mg/m/day, 6 dose-limiting...

Par Domaine 3 - U900, le 12/10/2019

. Buparlisib that targets PI3K was also shown to improve survival in combination with paclitaxel in an...

Par Domaine 3 - U900, le 12/10/2019

trials. We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for...

Par Domaine 3 - U900, le 12/10/2019

%) but 39% of patients had multiple locations. Median OS was 9.3 (95% CI: 7.9-11.8) months for the...

Par Domaine 3 - U900, le 12/10/2019


, ESR1, GATA3, KMT2C, NCOR1, AKT1, NF1, RIC8A and RB1) were more frequently mutated in metastatic breast...

Par Domaine 3 - U900, le 12/10/2019

tumors can guide the diagnosis of metastasis from HPV-related cervical cancer, but p16 positivity is...

Par Domaine 3 - U900, le 12/10/2019

...

Par Domaine 3 - U900, le 12/10/2019

age 30 up to age 90 compared to the most educated. The loss for women is twice as much with 3.5 years...

Par Domaine 3 - U900, le 12/10/2019

criteria. Reported hyperprogression incidence varied between 4% and 29% of all responses, mostly in multi-tumor...

Par Domaine 3 - U900, le 12/10/2019

challenges that still need to be overcome along with future perspectives for a broader implementation of...

Par Domaine 3 - U900, le 12/10/2019

An Amendment to this paper has been published and can be accessed via a link at the top of the...

Par Domaine 3 - U900, le 12/10/2019

pembrolizumab, an IgG4-kappa humanized monoclonal antibody against the programmed cell death protein 1 (PD-1...

Par Domaine 3 - U900, le 12/10/2019

carcinoma of the head and neck (R/M SCCHN). Recent data suggest that exposure to ICI improves response to...

Par Domaine 3 - U900, le 12/10/2019


frequently remained in episomal form (45.2%). The most common signature of HPV insertion was MJ-SC (26.9%), i.e...

Par Domaine 3 - U900, le 12/10/2019

approved among patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who...

Par Domaine 3 - U900, le 12/10/2019

have been yet proposed to conduct an IPD meta-analysis with competing risk endpoints. To fill this gap...

Par Domaine 3 - U900, le 12/10/2019